Abstract: The invention provides soybean plants having a novel determinant, Rps8, for resistance to Phytophthora sojae. The invention also provides methods for identifying germplasms that are either heterozygous or homozygous for Rps8 using marker assisted selection. Genetic markers with known chromosomal location that are associated with the Rps8 gene are used to confirm Rps8-derived Phytophthora sojae resistance in germplasms. Marker assisted selection also used when introgressing Rps8-derived soybean Phytophthora sojae resistance into non-resistant soybean germplasm or less resistant soybean germplasms.

Abstract: The invention provides soybean plants having a novel determinant, Rps8, for resistance to Phytophthora sojae. The invention also provides methods for identifying germplasms that are either heterozygous or homozygous for Rps8 using marker assisted selection. Genetic markers with known chromosomal location that are associated with the Rps8 gene are used to confirm Rps8-derived Phytophthora sojae resistance in germplasms. Marker assisted selection also used when introgressing Rps8-derived soybean Phytophthora sojae resistance into non-resistant soybean germplasm or less resistant soybean germplasms.

Abstract: The invention provides soybean plants having a novel determinant, Rps8, for resistance to Phytophthora sojae. The invention also provides methods for identifying germplasms that are either heterozygous or homozygous for Rps8 using marker assisted selection. Genetic markers with known chromosomal location that are associated with the Rps8 gene are used to confirm Rps8-derived Phytophthora sojae resistance in germplasms. Marker assisted selection also used when introgressing Rps8-derived soybean Phytophthora sojae resistance into non-resistant soybean germplasm or less resistant soybean germplasms.

Abstract: This invention provides a specific immunocapture ELISA for the quantitation of cancer procoagulant antibody complex (CPAC) in biological samples. In particular, this invention provides methods and techniques for specifically selecting and quantitatively measuring CPAC from a sample material using anti-CP antibodies followed by labeled anti-immunoglobulin antibodies. The amount of captured CPAC is then determined by measuring the amount of label in the captured CPAC.

Abstract: Peptidyl inhibitors, for example, peptidyl diazomethyl ketones and peptidyl methylsulfonium salts wherein the peptidyl moiety comprises two to ten amino acid residues inhibit cancer procoagulant, a cysteine proteinase, that is necessary for the viability of malignant cells. This invention provides for methods of cancer therapy and blood detoxification wherein these peptidyl inhibitors are used to destroy malignant cells.

Abstract: A procedure for the immunoassay of a proteolytic procoagulant enzyme in biological samples is described. The presence of the enzyme is indicative of malignant disease, and the immunoassay is used as a diagnostic test for cancer.

Abstract: Methods and techniques are described for detecting the presence of cancer procoagulant activity in blood serum. The method provides a means of distinguishing persons or animals having cancer from those who do not have cancer. The method involves techniques for processing serum such that the activity of cancer procoagulant can be measured while the activity of other coagulation enzymes in the serum is minimized or eliminated. Then the serum can be analyzed for cancer procoagulant activity.

Abstract: A chromatographic procedure for the purification of a proteolytic procoagulant enzyme from extracts of human and animal tumors. The extracts are sequentially contacted with a first benzamide affinity chromatographic resin, an agarose filtration gel, a second benzamide affinity chromatographic resin and a phenyl-sepharose hydrophobic chromatographic resin. The resulting enzyme is capable of producing anti-procoagulant antibody which, which used in an immunoassay, is diagnostic for malignancy.